NovaBay Pharmaceuticals, Inc. (NBY)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
3.57+0.20 (+5.93%)
At close: 4:02 PM EDT
People also watch:
CYCCOPXALPTNPIPIMUC
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open3.36
Prev Close3.37
Bid3.49 x 200
Ask3.55 x 700
Day's Range3.26 - 3.57
52wk Range1.75 - 11.50
1y Target EstN/A
Market Cap40.17M
P/E Ratio (ttm)-0.92
Beta-0.92
Volume68,445
Avg Vol (3m)114,078
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Accesswire12 days ago

    Dry Eye: A Growing Problem in an Aging Population

    About 10% of men - and 18% of women - over 50 suffer from painful dry eye, but new treatments can restore clear, healthy vision. BOWLING GREEN, OH / ACCESSWIRE / August 15, 2016 / Optometrist Mile Brujic, ...

  • NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
    Capital Cube15 days ago

    NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016

    Categories: Yahoo Finance Click here to see latest analysis NovaBay Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of NovaBay Pharmaceuticals, Inc. – Cempra, Inc., Tetraphase Pharmaceuticals, Inc., Johnson & Johnson and Oculus Innovative Sciences, Inc. (CEMP-US, TTPH-US, JNJ-US and OCLS-US) that have also reported ... Read more (Read more...)

  • Business Wire15 days ago

    NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing its prescription Avenova lid and lash hygiene product for the domestic eye care market, reports financial results for the three and six months ended June 30, 2016, and provides a business update.